Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 8
Submit an article Journal homepage
3,785
Views
10
CrossRef citations to date
0
Altmetric
Letters to the Editor

Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database

Elias JabbourDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Correspondence[email protected]
,
Matthias StelljesDepartment of Medicine, Hematology and Oncology, Universitätsklinikum Münster, Münster, Germany;
,
Anjali S. AdvaniDepartment of Hematology/Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA;
,
Daniel J. DeAngeloDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA;
,
Nicola GökbugetDepartment of Medicine II, University Hospital, Goethe University, Frankfurt, Germany;
,
David I. MarksBristol Haematology & Oncology Centre, University Hospitals Bristol NHS Trust, Bristol, UK;
,
Wendy StockSection of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA;
,
Susan O’BrienChao Family Comprehensive Cancer Center, University of California, Irvine, Orange, CA, USA;
,
Ryan D. CassadayDepartment of Medicine, University of Washington School of Medicine, Seattle, WA, USA;;Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA;
,
Tao WangGlobal Product Development – Oncology, Pfizer Inc, Cambridge, MA, USA;
,
Alexander NeuhofPfizer Pharma GmbH, Berlin, Germany
,
Erik VandendriesGlobal Product Development – Oncology, Pfizer Inc, Cambridge, MA, USA;
&
Hagop KantarjianDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA;
show all
Pages 2012-2015 | Received 24 Nov 2019, Accepted 29 Mar 2020, Published online: 07 May 2020

References

  • Tavernier E, Boiron JM, Huguet F, et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia. 2007;21(9):1907–1914.
  • O'Brien S, Thomas D, Ravandi F, et al. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer. 2008;113(11):3186–3191.
  • Gökbuget N, Stanze D, Beck J, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012;120(10):2032–2041.
  • Gökbuget N, Dombret H, Ribera JM, et al. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica. 2016;101(12):1524–1533.
  • Montalban-Bravo G, Kantarjian HM, Cortes JE, et al. Clinical impact of first complete remission (CR1) duration on outcome of patients with relapsed Philadelphia negative pre-B acute lymphoblastic leukemia (ALL). Blood. 2015;126(23):2504.
  • Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740–753.
  • Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019;125(14):2474–2487.
  • Cassaday RD, Alan Potts D Jr., Stevenson PA, et al. Evaluation of allogeneic transplantation in first or later minimal residual disease – negative remission following adult-inspired therapy for acute lymphoblastic leukemia. Leuk Lymphoma. 2016;57(9):2109–2118.
  • Shen Z, Gu X, Mao W, et al. Influence of pre-transplant minimal residual disease on prognosis after allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis. BMC Cancer. 2018;18:755.
  • Dombret H, Topp MS, Schuh AC, et al. Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma. 2019;60(9):2214–2222.
  • Topp MS, Zimmerman Z, Cannell P, et al. Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab. Blood. 2018;131(26):2906–2914.
  • Hoelzer D, Bassan R, Dombret H, et al. Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v69–v82.
  • Rowe JM. Prognostic factors in adult acute lymphoblastic leukaemia. Br J Haematol. 2010;150(4):389–405.
  • Kantarjian HM, DeAngelo DJ, Advani AS, et al. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol. 2017;4(8):e387–e398.
  • Marks DI, Kebriaei P, Stelljes M, et al. Outcomes of allogeneic stem cell transplantation after inotuzumab ozogamicin treatment for relapsed or refractory acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2019;25(9):1720–1729.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.